Global MedTech Ottobock continued its growth trajectory in the first half of 2025. The company recorded a 5.0% increase in revenue to EUR 801 million in the first six months of the year (H1 2024: EUR 763 million), with organic growth of 10.0%.
Strategic product launches and seven successful acquisitions significantly contributed to this positive development. At the same time, underlying EBITDA increased by 30.5% to EUR 180 million (H1 2024: EUR 138 million).
EBITDA margin increased by 4.4 percentage points to 22.5% (H1 2024: 18.1%) compared to the previous year. Free cash flow rose to EUR 93 million in the first half of the year (H1: EUR 36 million), nearly tripling compared to the same period last year.
In the first half of 2025, Ottobock launched four strategic key products – including the new Speedhand Solution in prosthetics, the next generation of the Exopulse Suit, and the active exoskeleton Volton.
Founded in Berlin in 1919, Ottobock combines over 100 years of tradition with innovative strength in the fields of prosthetics, neuro-orthotics and exoskeletons.
Ottobock develops innovative fitting solutions for people with limited mobility and is driving the digitalisation of the industry. The company is active in over 140 countries with around 9,100 employees.
